Capricor Therap receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Capricor Therapeutics Inc (CAPR)
Track today's live Capricor Therapeutics (CAPR) share price, performance and key data on this page with our current NASDAQ:CAPR stock exchange information. Analyse interactive charts and historical data, check technical buy and sell signals in real time, and follow the Capricor Therapeutics share price on the NASDAQ exchange. Use the dropdown to switch exchange for the CAPR share price, head to our technical summary section, which provides analysis on Capricor Therapeutics share price buy/sell indicators using real-time data (or discuss the Capricor Therapeutics (CAPR) stock price today with other investors in the Capricor Therapeutics NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ:CAPR share price (ISIN: US14070B3096) to enhance your trading decisions with our free investment tools and resources.
What Is the Capricor Therapeutics Inc Share Price Today?
The Capricor Therapeutics share price today is 3.850.
What Is the Stock Symbol for Capricor Therapeutics Inc
The stock symbol (or 'ticker') for Capricor Therapeutics Inc is "CAPR."
What Stock Exchange Does Capricor Therapeutics Inc Trade On?
Capricor Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Capricor Therapeutics Inc a Good Stock to Buy?
Determining whether Capricor Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Use the dropdown to select a relevant stock exchange for the current NASDAQ:CAPR share price (ISIN: US14070B3096) to enhance your trading decisions with our free investment tools and resources.
What Is the Capricor Therapeutics Inc Share Price Today?
The Capricor Therapeutics share price today is 3.850.
What Is the Stock Symbol for Capricor Therapeutics Inc
The stock symbol (or 'ticker') for Capricor Therapeutics Inc is "CAPR."
What Stock Exchange Does Capricor Therapeutics Inc Trade On?
Capricor Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Capricor Therapeutics Inc a Good Stock to Buy?
Determining whether Capricor Therapeutics (or any stock) is a good buy requires comprehensive market analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and more than 1,200 other metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.800
4.660
52 wk Range
2.960
40.370
Unusual trading volume
1/3
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.8004.660
52 wk Range
2.96040.370
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CAPR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
34.400
Upside
+793.51%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Capricor Therap receives Investment Bank Analyst Rating Update- Investing.com
Pro
- Capricor Therap receives Investment Bank Analyst Rating Update
- Investing.com
Pro 
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
1 Buy
9 Hold
0 Sell
Ratings:
10 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 34.400
(+793.51% Upside)
Capricor Therapeutics Inc Earnings Call Summary for Q1/2026
- Capricor reported Q1 2026 EPS of -$0.59, missing estimates of -$0.52 by 13.46%; net loss widened to $33.9M amid increased investments
- Operating expenses surged 47.2% YoY to $36.8M as company invests in regulatory activities, manufacturing expansion, and commercial infrastructure
- Lead product deramiocel remains under FDA review with PDUFA date set for August 2026; no revenue expected until approval and launch
- Strong balance sheet with cash reserves sufficient to fund operations through Q4 2027; potential Priority Review Voucher upon approval
- Stock rose 0.6% post-earnings to $32.09 despite miss; analyst price targets range from $43-$63, reflecting confidence in regulatory progress
Last Updated: 12/05/2026, 23:00
Read Full TranscriptEarnings
Latest Release
12/05/2026
EPS / Forecast
-0.59 / -0.52
Revenue / Forecast
-- / --
Compare CAPR to Peers and Sector
Metrics to compare | CAPR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCAPRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.9x | −1.8x | −0.3x | |
PEG Ratio | 0.03 | −0.04 | 0.00 | |
Price/Book | 0.8x | 1.9x | 2.6x | |
Price / LTM Sales | - | 10.0x | 3.0x | |
Upside (Analyst Target) | 29.9% | 333.1% | 56.3% | |
Fair Value Upside | Unlock | 12.2% | 9.2% | Unlock |
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. In addition, it engages in developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases; It has license agreement with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform. The company was founded in 2005 and is headquartered in San Diego, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Capricor Therapeutics (NASDAQ: CAPR) Share Price Today?
The Capricor Therapeutics stock price today is 3.850 USD.
What Stock Exchange Does Capricor Therapeutics (CAPR) Trade On?
Capricor Therapeutics is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Capricor Therapeutics?
The stock symbol (also called a 'ticker') for Capricor Therapeutics is "CAPR."
What Is the Current Capricor Therapeutics Market Capitalisation?
As of today, Capricor Therapeutics (NASDAQ: CAPR) market cap is 222.960M USD.
What Is Capricor Therapeutics's (CAPR) Earnings Per Share (TTM)?
The Capricor Therapeutics EPS is currently -2.318 (Trailing Twelve Months).
When Is the Next Capricor Therapeutics Earnings Date?
Capricor Therapeutics's next earnings report will be released on 12/08/2026.
Is CAPR a Buy or Sell From a Technical Analyst Perspective?
Based on today's Capricor Therapeutics moving averages and other technical indicators, the daily buy/sell signal for CAPR stock is Strong Sell.
How Many Times Has Capricor Therapeutics Stock Split?
Capricor Therapeutics has split 2 times. (See the CAPR stock split history page for full effective split date and price information.)
How Many Employees Does Capricor Therapeutics Have?
Capricor Therapeutics has 231 employees, based on their latest Companies House report.
What is the current trading status of Capricor Therapeutics (NASDAQ: CAPR)?
As of 02/08/2026, Capricor Therapeutics (CAPR) is trading at a share price of 3.850 USD, with a previous close of 4.190 USD. The stock has fluctuated within a day range of 3.800 USD to 4.660 USD, while its 52-week range spans from 2.960 USD to 40.370 USD.
What Is Capricor Therapeutics (CAPR) Price Target According to Analysts?
The average 12-month price target for Capricor Therapeutics is 34.400 USD, with a high estimate of 54 USD and a low estimate of 7 USD. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Neutral. The stock has an +793.51% Upside potential.
What Is the CAPR Premarket Price?
CAPR's last pre-market stock price is 3.980 USD. The pre-market share volume is 184,180.000, and the stock has decreased by -0.210, or -5.010%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.